The global single-use bioprocessing market is expected to grow from USD 30.12 billion in 2025 to USD 122.92 billion by 2035 at a CAGR of 15.1%. Driven by technological breakthroughs in bioreactor scalability (up to 6,000L), 40-50% CAPEX reductions, and FDA approvals of 16 single-use-manufactured biologics in 2024, the market is becoming the standard for commercial biomanufacturing. Major players are expanding capacity significantly, with CDMOs like WuXi Biologics managing substantial backlogs.

The global continuous bioprocessing market is projected to grow from USD 319.77 million in 2025 to USD 2,331.98 million by 2035 at a CAGR of 21.98%. Driven by demand for biosimilars and complex biologics, manufacturers are shifting from traditional fed-batch to continuous methods, achieving 50% cost reductions and significant sustainability improvements. North America leads with 39% market share, while Asia Pacific rapidly expands capacity. Major pharmaceutical and biotech companies are deploying billions in capital investments to modernize manufacturing infrastructure.

The filtration in biologics market is projected to experience significant growth from 2024 to 2034, driven by increasing demand for monoclonal antibodies, vaccines, and cell and gene therapies, with North America leading and Asia Pacific showing the fastest growth potential.

Repligen, a bioprocessing technology company, reported mixed Q4 results. While adjusted EPS exceeded expectations, GAAP gross margin declined significantly due to restructuring and other costs. The company is focused on product innovations and strategic acquisitions to drive growth.

The global chromatography system market is expected to grow at a CAGR of 6.6% from 2024 to 2034, driven by increasing applications in the biotechnology sector and technological advancements that simplify procedures and reduce human error.

BioLife Solutions, a leading developer and supplier of bioproduction tools and services for the cell and gene therapy market, has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors. Hunt's appointment is expected to strengthen BioLife's focus on extending its position as a provider of industry-leading solutions for bioproduction workflows in the cell and gene therapy market.

Repligen Corporation, a life sciences company, has published its 2023 Corporate Sustainability Report, highlighting progress in advancing its sustainability strategy across various impact areas. The report includes disclosures aligned with key reporting frameworks, and the company has committed to net-zero emissions by 2050.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Deutsche Bank analyst Justin Bowers upgraded the rating for Repligen Corporation (NASDAQ:RGEN) from Hold to Buy, but lowered the price target from $180 to $155. Repligen shares fell 0.4% to close at $123.15 on Tuesday. See how other analysts view this stock. Wolfe Research analyst Steven Chubak upgraded Robinhood Markets, Inc. (NASDAQ:HOOD) from Peer Perform to Outperform, while announcing a price target of $29. Robinhood shares gained 3.6% ...Full story available on Benzinga.com

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup raised the price target for NVIDIA Corporation (NASDAQ:NVDA) from $126 to $150. Citigroup analyst Atif Malik maintained a Buy rating. NVIDIA shares gained 6.8% to close at $126.09 on Tuesday. See how other analysts view this stock. Truist Securities raised the price target for Rivian Automotive, Inc. (NASDAQ:RIVN) from $10 to $13. Truist Securities analyst Jordan Levy maintained a Hold rating. Rivian Automotive shares gained 8.6% to close at $11.96 on Tuesday. See how other analysts view this stock. BTIG cut Exact Sciences Corporation (NASDAQ:EXAS) price target from $80 to $70. BTIG analyst Mark Massaro maintained a Buy rating. Exact Sciences shares fell 1.4% to close at $41.37 on Tuesday. See how other analysts view this stock. Morgan Stanley boosted the price target for FedEx Corporation (NYSE:Full story available on Benzinga.com

Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Repligen (RGEN) appoints Olivier Loeillot as the company's new president and chief executive officer, effective from Sep 1, 2024. Stock falls on the news.

Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024 Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024